Therapy for post-transplant relapse of paediatric ALL is limited. Standardised curative approaches are not available. We hereby describe our local procedure in this life-threatening situation. A total of 101 ALL patients received their first allogeneic stem cell transplantation (SCT) in our institution. After relapse, our primary therapeutic goal was to cure the patient with high-dose chemotherapy or specific immunotherapy (HDCHT/SIT) followed by a second SCT from a haploidentical donor (transplant approach). If this was not feasible, low-dose chemotherapy and donor lymphocyte infusions (LDCHT+DLI) were offered (non-transplant approach). A total of 23 patients suffered a post-transplant relapse. Eight patients received HDCHT/SIT, followed by haploidentical SCT in 7/8. Ten received LDCHT+DLI. The eight patients treated with a second transplant and the ten treated with the non-transplant approach had a 4-year overall survival of 56% and 40%, respectively (P = 0.232). Prerequisites for successful treatment of post-transplant relapse by either a second transplant or experimental non-transplant approaches are good clinical condition and the capacity to achieve haematological remission by the induction treatment element.
INTRODUCTION
Relapse remains the major cause of treatment failure after allogeneic stem cell transplantation (allo-SCT) in patients with ALL. [1] [2] [3] [4] [5] [6] [7] [8] In the past, curative therapeutic options for this condition have been limited. Before the potent leukaemia-specific treatment procedures such as chimeric Ag receptor T-cell therapy 9 become applicable for the majority of patients, alternative rescue approaches were desperately needed. In our opinion, to date only a second allo-SCT can offer a realistic curative treatment option for these patients. 1, [10] [11] [12] [13] However, a standardized approach, which could enable a curative perspective, is currently not available. We hereby present findings from our Frankfurt practice regarding the treatment of post-transplant relapse based on a retrospective analysis of the outcome of 101 children and adolescents with ALL, who received their first allo-SCT in our institution between 2005 and 2014. We evaluated a curative second transplant as well as an experimental non-transplant treatment approach and give a proposal for treatment options of post-transplant relapse considering the latest therapeutic developments in the field.
MATERIALS AND METHODS Patients
In this single-centre, retrospective study, all paediatric patients with a primary diagnosis of ALL who received their first allo-SCT in CR in our transplant centre in Frankfurt/Main, Germany (EBMT Code CIC 0138) between 2005 and 2014 were included. The institutional ethics committee approved this study (No. 529/15). Allo-SCT and other therapeutic approaches were conducted after written informed consent was obtained.
Aims and definitions
The primary objective of this study was to identify and evaluate therapeutic options in the event of relapse after first allo-SCT.
Overall survival (OS) after relapse was the primary end point, considering the date of relapse after the first SCT as the starting point and the date of death, or of last follow-up as the end of the interval. The secondary end points were OS, event-free survival, cumulative incidence of relapse and non-relapse mortality (NRM) after first allo-SCT, using the date of the first SCT as the starting point and the date of the respective event, or of last follow-up as the end of the interval. Relapse after SCT was defined as the presence of ⩾ 5% of blasts, which were found in the bone marrow (BM) by morphological analysis.
Our strategy to treat post-transplant relapse was as follows: high-dose chemotherapy or specific immunotherapy (HDCHT/SIT), for example, blinatumomab to induce remission followed by a second allo-SCT from a haploidentical donor, which was offered if the patient was in good clinical condition (Karnofsky index ⩾ 80%). If a second SCT did not seem feasible, a combination of low-dose chemotherapy and donor lymphocyte infusions (LDCHT+DLI) was offered ( Figure 1 ). from day − 15 to − 13), etoposide (totally 3 × 100 mg/m 2 ; daily 100 mg/m 2 from day − 15 to − 13), alemtuzumab (total 5 × 0.1 mg/kg BW; daily 0.1 mg/ kg BW from day − 12 to − 8), fludarabine (total 4 × 40 mg/m 2 ; daily 40 mg/ m 2 from day − 8 to − 5), thiotepa (totally 2 × 5 mg/kg BW; administered on day − 4) and melphalan (total 2 × 70 mg/m 2 ; daily 70 mg/m 2 from day − 3 to − 2). Post-transplant immunosuppression was not administered. 14, 15 Statistical analysis
We used the reverse Kaplan-Meier method 16 to estimate the median survival follow-up time. The median time to engraftment was estimated by the cumulative incidence considering other events such as early death as competing risks. Engraftments of leukocytes, neutrophils and thrombocytes were defined according to Mackall et al. 17 The probabilities of event-free survival and OS were calculated by the Kaplan-Meier method and compared using the log-rank test. Events for event-free survival were defined as relapse or NRM. NRM was defined as death of any cause without relapse. NRM and disease-free survival were considered competing risks in the calculation of cumulative incidence of relapse.
We reported a 5-year OS probability estimate after the first SCT and a 4-year OS (4y-OS) probability estimate after post-transplant relapse to account for the interval between the first SCT and relapse (median of 8 months (1.9-39.7)). A P-value o0.05 was considered statistically significant. Data analysis was performed using R version 3.2.1 18 and was conducted according to the EBMT statistical guidelines. 19 Date of last follow-up was 1 May 2015. 
RESULTS
Outcome after first allo-SCT A total of 101 children with ALL received their first allo-SCT in our institution between 2005 and 2014. Detailed patient characteristics are presented in Table 1 . The immunophenotypes were B-precusor-ALL (n = 67), T-ALL (n = 27) and mixed phenotype ALL (n = 7). The median age at the time of the first SCT was 11 years (range 0.2-25) and the median follow-up time of survivors was 5.2 years (range 0.5-10.5). Patients were grafted from matched unrelated donor (n = 68), matched sibling donor (n = 21), mismatched family donor (n = 11), and mismatched unrelated donor (n = 1) in first CR1, (n = 55), CR2 (n = 30) and 4CR2 (n = 16). The transplanted stem cells were derived from BM in n = 75 and from PBSC in n = 26 transplant procedures. In vitro T-cell depletion was performed in 13 cases. Preparative regimens were myeloablative (n = 91) or reduced-intensity conditioning (n = 10), and were based on TBI (n = 84) or chemotherapy (n = 17). After transplant, 69/101 (68%) patients remained in CR, 9/101 (9%) experienced NRM and 23/101 (23%) suffered a relapse ( Figure 2 ). For the entire cohort (n = 101), the probability of event-free survival (5 years) was 66% (±5%, events = 32), 5 year cumulative incidence of relapse was 25% (±4%, events = 23) and 5 year NRM was 9% (±3%, events = 9).
Incidence and site of post-transplant relapse Twenty-three of 101 (23%) patients relapsed after their first SCT. The relapse site was isolated BM in 16/23 (69%), combined (BM and extra medullary) in 2/23 (9%) and isolated extra medullary in 5/23 (22%, Table 2 ). None of these patients suffered from GvHD or was on immunosuppression at the time of relapse.
Approaches to treat post-transplant relapse The decision how to treat post-transplant relapse was made according to the flowchart illustrated in Figure 3 . The time point of post-transplant relapse was of utmost importance. Salvage therapy with blinatumomab as first-line and HDCHT (DaunoXome-fludarabine and high-dose cytarabine or clofec) as second-line therapy was recommended if relapse occurred after d365 and the patient was in good clinical condition. A second allo-SCT from a haploidentical donor was recommended if remission was achieved after salvage induction therapy. In the event of relapse before d365, the patient was considered for a second allo-SCT if relapse occurred after day 200. If the relapse occurred before day 200 or a second SCT did not seem feasible, LDCHT+DLI was offered (Figure 1 ). If remission was achieved after induction therapy, a second allo-SCT was considered if the clinical condition allowed for this procedure. If a second SCT did not seem feasible and the patient was in remission, LDCHT+DLI was continued.
Consequently, we considered two therapeutic approaches to treat children, who had relapsed after first allo-SCT: (1) a transplant approach and (2) an experimental non-transplant approach.
Treatment after post-transplant relapse Eight of 23 (35%) patients received HDCHT/SIT, followed by a haploidentical SCT in 7/8, whereas 10/23 (43%) were treated with LDCHT+DLI (± local therapy) and 5/23 (22%) patients received palliative care (Table 2, Figure 2 ).
Transplant approach: salvage HDCHT/SIT and haploidentical SCT Eight of 23 children received salvage HDCHT/SIT. Three of the eight patients were treated with IV idarubicine/DaunoXome, fludarabine and high-dose cytarabine, 20 and 2/8 children received IV clofarabine-based chemotherapy 21 because the maximum recommended cumulative dose of anthracyclines had been Abbreviations: BM = bone marrow; MAC = myeloablative; MMUD = mismatched unrelated donor; MSD = matched sibling donor; MUD = matched unrelated donor; RIC = reduced-intensity conditioning; SCT = stem cell transplantation.
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These eight patients achieved remission again and were scheduled for haploidentical SCT. One of the eight died from NRM after having received DaunoXome-fludarabine and highdose cytarabine before a second SCT could be performed. Seven of eight underwent a second SCT from a haploidentical donor (Table 2, Figure 2 ).
Experimental non-transplant approach: combination of LDCHT and DLI (The FRALLPOST 2004 protocol) Ten of 23 patients were treated with LDCHT+DLI ( ± local therapy) as described in Figure 1 , because a second SCT did not seem feasible. This therapeutic approach consisted of systemic treatment and local therapy of the central nervous system. The systemic treatment consisted of different combinations of intravenously and orally administered drugs supported by cellular immunotherapy (DLI). Central nervous system treatment consisted of repetitive intrathecal administration of cytarabine, methotrexate and prednisone, regardless of whether central nervous system relapse was present. In the case of non-central nervous system extra medullary relapse (testis (n = 2), intestine (n = 1)), local surgical treatment was performed (Table 2, Figure 2 ). This LDCHT+DLI approach was conducted until the analysis of minimal residual disease was negative, but was continued for at least 52 weeks.
Bone marrow puncture after induction therapy within the fifth week of the protocol was of critical importance in this therapeutic approach. Therapy could solely have a curative intent if remission has been achieved at this point of time. In the event of nonremission, clinicians should balance between reasons to continue therapy with palliative intent and treatment termination (Figure 1 
Palliative care
Five of 23 patients received palliative care because further therapy was not feasible or was not wanted by the patient and parents (Table 2, Figure 2 ).
Outcome after post-transplant relapse Eight of 23 children received salvage HDCHT/SIT. One patient died before a second SCT could be performed. Seven patients underwent haploidentical SCT. Five of 7 (71%) patients remained in CR. A second SCT did not seem feasible in 10/23 patients after post-transplant relapse. They received LDCHT+DLI ( ± local therapy). Four of 10 (40%) patients remained in CR. Five of 23 children received palliative care and died of relapse (Table 2, Figure 2 ). In summary, our treatment efforts after relapse resulted in a 4y-OS of 39% ( ±10%, events = 14) for the cohort of 23 patients (Figure 4a) . Intention to treat analyses according to the two different treatment approaches resulted in the following survival probabilities: treatment of 8 patients with the transplant approach resulted in a 4y-OS of 56% (±20%, events = 3). Treatment of 10 patients with the experimental non-transplant approach resulted in a 4y-OS of 40% (±16%, events = 6, P = 0.232, Figure 4b , Table 2 ). Finally, our treatment efforts after relapse led to a 5-year OS for the whole cohort of 101 patients of 76% (±4%, events = 23).
DISCUSSION
Counselling and treating patients with haematological malignancies in the event of a relapse after allogeneic SCT is a major challenge, and curative therapeutic options are limited. In the past, only a second allo-SCT could present a curative option for paediatric 1 as well as adult patients. [2] [3] [4] [5] [6] [7] 10, 12, 13 A standardized procedure to enable a curative perspective after post-transplant relapse is currently not available.
Three important questions must be answered in a posttransplant relapse situation. (1) Which patients are eligible for a second SCT? (2) How should this SCT be conducted? (3) Which patients are not eligible for a second SCT, and thus which alternative therapeutic approaches could be offered until new therapies (for example, chimeric Ag receptor T-cell therapy) 9 become widely available?
Prerequisites for a second SCT are good clinical condition of the patient, and the availability of both a donor and a salvage therapy to induce remission again. Nevertheless, a second SCT remains a dangerous and expensive treatment modality, particularly, in paediatric patients who have received substantial pre-transplant treatment. The question of whether a second SCT is ethically justified has to be answered individually for each patient.
The aim of this retrospective single-centre study of 101 children and adolescents with ALL, who received their first allo-SCT in our institution between 2005 and 2014, was to evaluate the treatment options in the event of relapse after first allo-SCT. Twenty-three of 101 (23%) patients relapsed after their first SCT. We considered two treatment options in this situation: a transplant as well as an experimental non-transplant approach. Seven children received a second SCT from a haploidentical donor after having responded to salvage HDCHT/SIT. Five of the seven patients remained in CR. A second SCT did not seem feasible in all patients. Experimental LDCHT+DLI was offered to those patients. The combination of LDCHT and DLI was chosen, because it was well known that the transfusion of donor lymphocytes alone in the event of frank relapse could not offer a realistic chance of inducing remission. 23 LDCHT+DLI was administered to induce remission to buy time to open the window for a second SCT or, if not feasible, to potentially induce long-term remission by this low-dose therapy alone. Ten patients received LDCHT+DLI. Four of these 10 patients remained in CR.
The transplant approach led to a 4y-OS of 56% (±20%, events = 3), whereas the experimental non-transplant approach resulted in a 4y-OS of 40% (±16%, events = 6, P = 0.232). In summary, 9/18 (50%) patients who received treatment of relapse after allo-SCT survived their disease, and post-relapse treatment efforts resulted in a 5-year OS of 76% for the entire cohort of 101 patients.
This study showed several limitations: (i) its retrospective and single-centre design, (ii) the limited number of patients, who received treatment of post-transplant relapse and (iii) the lack of a control group, who received 'standard therapy'. Nevertheless, the results of our two approaches to treat post-transplant relapse were encouraging. Therefore, we embedded our experience gained in this study in a proposal for treatment options of post-transplant relapse ( Figure 5 ), which also includes other current experimental therapeutic approaches. 9, 24 Before day 365, n =15 Consideration for second SCT, if: Table 2 ). **Further therapy not wanted. Figure 1) ; HDCHT, high-dose chemotherapy; LDCHT, low-dose chemotherapy; MRD, minimal residual disease; SCT, stem cell transplantation; SIT, specific immunotherapy. *Patients, who do not achieve CR, should be considered for palliative care; **Rettinger et al.
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